Oh, I'm sorry.
Yes, we continue to work on that. As the committee will probably remember, we do have a national plan for the health sector, as well as an international plan. We have a North American plan in place that continues to be revised.
We're unique in the world, still, in having a vaccine contract with a domestic manufacturer to produce sufficient vaccine for the total population. We also have in place stockpiles of antivirals, both held jointly with the provinces and territories as well as our own federal stockpile, that should be sufficient to treat anybody who needs treatment in the interim, until we have the vaccine in place, and for those for whom the vaccine is not effective. Planning at every level is taking place.
In terms of the shelf life, yes, some are starting to expire now. We're in active conversations with the provinces and territories about how we deal with that.
We're also adding to our national stockpile and looking to replenish some of the existing stock with new stock, including adjusting the kinds we have--adding, for example, amantadine, as we recognize resistance, and increasing the amount of Relenza--as well as having more pediatric doses in place.